Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) EPS (Basic) (2016 - 2026)

Lexaria Bioscience's EPS (Basic) history spans 12 years, with the latest figure at $0.13 for Q1 2026.

  • Quarterly results put EPS (Basic) at $0.13 for Q1 2026, down 64.65% from a year ago — trailing twelve months through Feb 2026 was $1.18 (down 39.56% YoY), and the annual figure for FY2025 was $1.63, up 66.76%.
  • EPS (Basic) for Q1 2026 was $0.13 at Lexaria Bioscience, down from $0.16 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.91 in Q4 2024 to a low of -$0.98 in Q2 2022.
  • The 5-year median for EPS (Basic) is $0.3 (2022), against an average of $0.18.
  • The sharpest move saw EPS (Basic) tumbled 377.78% in 2022, then surged 321.78% in 2024.
  • Year by year, EPS (Basic) stood at $0.3 in 2022, then fell by 28.35% to $0.22 in 2023, then surged by 321.78% to $0.91 in 2024, then tumbled by 82.6% to $0.16 in 2025, then decreased by 20.66% to $0.13 in 2026.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at $0.13, $0.16, and $0.37 for Q1 2026, Q4 2025, and Q3 2025 respectively.